Dual regulatory holds on TXM leave Traws with $5M cash and a resubmission race against a Q1 2027 cliff

Traws Pharma is a clinical-stage antiviral company developing tivoxavir marboxil, a once-monthly treatment to prevent influenza, which is not yet approved and currently faces regulatory holds from both U.S. and U.K. authorities.

Traws built its influenza antiviral franchise around tivoxavir marboxil, a once-monthly prophylactic, now blocked by both an MHRA toxicology rejection and a U.S. FDA clinical hold simultaneously. The thesis survives only if MHRA accepts the revised toxicology package and the challenge study delivers proof-of-concept before cash runs out in Q1 2027. With $5M on hand, milestone-gated warrants that cannot fund operations independently, and an FDA hold still unresolved, the financing structure is structurally fragile.